Dataset Information

[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].

ABSTRACT: With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations. .

SUBMITTER: Zhang T

PROVIDER: S-EPMC8143967 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].

Zhang Tongmei T Li Baolan B

Zhongguo fei ai za zhi = Chinese journal of lung cancer 20210301 3

With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing eff ...[more]

PMID: 33819969

Similar Datasets

Project description:BackgroundTreatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved with target therapies, resistance invariably occurs and recourse to alternative treatments is unavoidable. Immune checkpoint inhibitors (ICIs) role and the best setting of immunotherapy administration in oncogene-driven NSCLC are matter of debate.MethodsWe performed a systematic literature review through PubMed, in order to gather all the available information regarding ICI activity and efficacy in oncogene-addicted NSCLC, from both prospective trials and retrospective series. A meta-analysis of objective response rate in different molecular subgroups was provided. Combinatorial strategies including ICIs and related toxicities were also recorded.ResultsEighty-seven studies were included in the qualitative analysis. EGFR mutation may be a biomarker of poor response to single-agent ICIs (7% of EGFR-mutant NSCLC patients achieved disease response in prospective trials), while encouraging results have been shown with combination strategies. KRAS-mutated disease (response rate, RR, 22%) has different clinical and pathological characteristics, and the co-existence of additional mutations (e.g., STK11 or TP53) influence tumor microenvironment and response to immunotherapy. Other molecular alterations have been marginally considered prospectively, and data from clinical practice are variegated, given poor effectiveness of ICIs in ALK-rearranged disease (RR 9.5%, pooling the data of retrospective studies) or some encouraging results in BRAF-(RR 25%, retrospective data) or MET-driven one (with estimations conditioned by the presence of both exon 14 skipping mutations and gene amplification in reported series).ConclusionsIn oncogene-addicted NSCLC (with the exception of KRAS-mutated), ICIs are usually administered at the failure of other treatment options, but administering single-agent immunotherapy in later disease phases may limit its efficacy. With the progressive administration of TKIs and ICIs in early-stage disease, molecular characterization will become fundamental in this setting.

Dataset Information

[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].

Publications

[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

[Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer].

Publications

[Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer].

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].

[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].